The PE Ratio as of November 2024 (TTM) for Royalty Pharma plc (RPRX) is 10.41

According to Royalty Pharma plc’s latest financial reports and current stock price. The company's current PE Ratio is 10.41. This represents a change of -94.40% compared to the average of 185.74 of the last 4 quarters.

Royalty Pharma plc (RPRX) Historical PE Ratio (quarterly & annually)

How has RPRX PE Ratio performed in the past?

The mean historical PE Ratio of Royalty Pharma plc over the last ten years is 68.14. The current 10.41 PE Ratio has changed 1.43% with respect to the historical average. Over the past ten years (40 quarters), RPRX's PE Ratio was at its highest in in the March 2024 quarter at 701.85. The PE Ratio was at its lowest in in the March 2022 quarter at -148.32.

Royalty Pharma plc (RPRX) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Royalty Pharma plc PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Royalty Pharma plc (RPRX) Average PE Ratio

How has RPRX PE Ratio performed in the past?

The current PE Ratio of Royalty Pharma plc (RPRX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Royalty Pharma plc (RPRX) PE Ratio vs. Peers

How is RPRX’s PE Ratio compared to its peers?

Royalty Pharma plc’s PE Ratio is greater than Prime Medicine, Inc. (-1.75), greater than Reneo Pharmaceuticals, Inc. (-10.76), greater than Ginkgo Bioworks Holdings, Inc. (-0.58), greater than Ocean Biomedical, Inc. (-0.71), greater than Adaptive Biotechnologies Corporation (-3.54), greater than VectivBio Holding AG (-7.94), greater than Kinnate Biopharma Inc. (-1.57), greater than Ikena Oncology, Inc. (-1.38), greater than Ascendis Pharma A/S (-16.63), greater than Apellis Pharmaceuticals, Inc. (-15.24), greater than BeiGene, Ltd. (-23.45), greater than Akero Therapeutics, Inc. (-9.58), greater than Blueprint Medicines Corporation (-46.60), greater than Iovance Biotherapeutics, Inc. (-6.32), greater than CureVac N.V. (5.18), greater than Madrigal Pharmaceuticals, Inc. (-14.57), greater than Mirati Therapeutics, Inc. (-11.26), greater than IVERIC bio, Inc. (-27.51), greater than Amylyx Pharmaceuticals, Inc. (-1.38), greater than Karuna Therapeutics, Inc. (-37.08), greater than Day One Biopharmaceuticals, Inc. (-15.73),

Build a custom stock screener for Royalty Pharma plc (RPRX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Royalty Pharma plc using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Royalty Pharma plc (RPRX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Royalty Pharma plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.